-
For failing to comply with the regulations, the pharmaceutical company was fined 1,000,000 yuan, and the manager of the purchasing department was banned from entering the industry for life!
Time of Update: 2022-05-21
A pharmaceutical company in Yunnan and its principal were fined and confiscated more than one million yuan for failing to comply with the quality management standards for drug business and failing to record the purchase and sale of drugs in accordance with the regulations.
-
Bihuan Pharmaceutical's Doxycycline Hydrochloride Tablets Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2022-05-21
com database, there are currently 61 domestic manufacturers of doxycycline hydrochloride tablets of the same variety, of which 3 manufacturers can be queried for the current consistency evaluation, namely the original research Pfizer Pharmaceutical Co.
-
Domestic pharmaceutical companies are accelerating their pace of innovation, and R&D expenses are expanding
Time of Update: 2022-05-21
In addition, the data also shows that in 2021, the research and development expenses of 34 Hong Kong-listed pharmaceutical companies will exceed 500 million yuan, of which 18 companies will invest more than 1 billion yuan in research and development .
-
The global pharmaceutical company landscape is reshuffled, and three new pharmaceutical companies enter the top 20 in terms of revenue
Time of Update: 2022-05-21
It is reported that Huizhi will achieve total global revenue of US$17.
21 billion, an increase of 2% year-on-year, and accounted for 13% of Huizhi's total global revenue .
Among them, the pharmaceutical business brought in US$52 billion in revenue, a year-on-year increase of 13.
-
First imitation!
Time of Update: 2022-05-21
During the whole process of preoperative anesthesia, intraoperative sleep, and postoperative awakening, three types of drugs, such as sedatives, analgesics, and muscle relaxants, are usually required to act synergistically, and to reverse the patient's functional state in a timely manner .
-
The State Food and Drug Administration issued the "Guidelines for Pharmacovigilance Inspection"
Time of Update: 2022-05-21
3. All provincial drug supervision and administration departments should incorporate the relevant content of pharmacovigilance inspection in their daily supervision work in light of the supervision actuality of their respective administrative regions, formulate inspection plans scientifically, organize their implementation in an orderly and efficient manner, and further refine the relevant work content, Improve relevant work requirements and effectively implement territorial supervision responsibilities .
-
Pay attention to the dynamics of the consistency evaluation of generic drugs, which varieties have been reviewed recently?
Time of Update: 2022-05-20
Peking University Pharmaceuticals: Compound Sulfamethoxazole Tablets Reviewed Peking University Pharmaceuticals announced on the evening of April 15 that the company recently received the “Approval Notice for Supplementary Drug Application” approved and issued by the State Food and Drug Administration, and the company’s declared “Compound Sulfamethoxazole Tablets” (Specification: Sulfamethoxazole 0.
-
AstraZeneca/Daisankyo's blockbuster ADC for the treatment of non-small cell lung cancer received priority review
Time of Update: 2022-05-20
S. FDA for the treatment of patients with unresectable or metastatic non-small cell lung cancer (NSCLC) harboring HER2 mutations .
"References:[1] Enhertu granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.
-
Potentially best in class!
Time of Update: 2022-05-20
ASC11 is an oral small molecule drug candidate targeting 3CLpro independently developed using proprietary technologies including molecular simulation docking and has global intellectual property rights .
In addition, Ascletis' second 3CLpro drug candidate showed antiviral activity and safety window consistent with ASC11 in Vero E6 cells .
-
The next round of competition for domestic PD-1 is shifting to overseas markets
Time of Update: 2022-05-20
On April 13, 2022, Junshi Bio announced that toripalimab, an anti-PD-1 monoclonal antibody independently developed by the company for the treatment of small cell lung cancer (SCLC), has been approved by the U.
-
Domestic neutral borosilicate glass has huge potential space for upgrading, but there are still several problems to be solved
Time of Update: 2022-05-20
In the face of considerable potential space for upgrading, more and more domestic enterprises have joined the neutral borosilicate glass industry, and the entire pharmaceutical packaging industry has shown a thriving scene .
-
The protection of raw materials for Chinese medicine to fight the epidemic may become a problem if it is recognized by the WHO!
Time of Update: 2022-05-20
Raw material supply: more than half of the varieties have short growth cycles, and new production will surge in the future Figure 5: The ninth edition of the diagnosis and treatment protocol involves the growth cycle of raw materials Among the 67 kinds of Chinese medicinal materials involved in the ninth edition of the diagnosis and treatment plan, 31 have a growth cycle of 1 year, accounting for 46.
-
In 2022, the procurement of medicines and consumables will continue to accelerate and expand
Time of Update: 2022-05-20
For example, recently, the Henan Provincial Medical Insurance Bureau announced that Henan, Shanxi, Inner Mongolia, Hubei, Hunan, Guangxi, Hainan, Chongqing, Guizhou, Qinghai, Ningxia, Xinjiang, Xinjiang Construction Corps and other thirteen provinces (districts, cities, and Corps) form provinces The international alliance plans to carry out centralized and volume-based procurement of the second and fourth batches of drugs that have expired in the state-organized centralized procurement of drugs .
-
In April, good news for the hypoglycemic drug market continued
Time of Update: 2022-05-20
On April 15, the NMPA released the drug approval information, which showed that Shandong New Era Pharmaceuticals' metformin hydrochloride sustained-release tablet category 4 generic marketing application was approved .
-
Active financing in the domestic medical and health field: 20 financings in one week, with a total financing of over 1.2 billion
Time of Update: 2022-05-20
From the perspective of the financing amount of a single project, the medical and health enterprises that have invested more than 100 million yuan mainly include companies such as Beilai Bio, Saipu Instrument, and Antikang Bio .
-
Local pharmaceutical companies need to make efforts from three aspects to solve the "disaster in going to sea"
Time of Update: 2022-05-20
In addition, Boaoxin also recently announced that it has reached a cooperation with Pyxis Oncology, granting Pyxis Oncology the exclusive license rights for the global development and commercialization of anti-Siglec-15 monoclonal antibody BSI-060T except for Greater China .
-
The research and development of peptide drugs is hot, and local pharmaceutical companies continue to make breakthroughs and deepen their layout.
Time of Update: 2022-05-20
In recent years, the research and development of domestic peptide drugs has been hot, and many local pharmaceutical companies have not only stayed in the field of generic drugs, but have continued to make breakthroughs and in-depth layouts .
-
List of recent Chinese herbal medicine prices: Forsythia prices continue to rise
Time of Update: 2022-05-20
Conclusion In general, most of the Chinese medicinal materials have been affected by the epidemic recently, and most of the varieties have been flat, but there are also varieties such as Forsythia suspensa with strong prices, while the trend of windproof and bergamot seems to be relatively sluggish .
-
The chairman of another pharmaceutical company resigned, and nearly 100 senior executives in the pharmaceutical industry left during the year
Time of Update: 2022-05-20
On March 11, Heavy Pharmaceutical Holdings announced that Liu Shaoyun had applied to resign as the company's chairman, director, member and convener of the strategic development and investment committee of the board of directors, and member of the nomination committee of the board of directors due to personal reasons .
-
The two companies cooperate to promote the broader integration of AI and innovative molecular research and development
Time of Update: 2022-05-20
On April 26, 2021, Suozhi Bio, an AI-driven new biopharmaceutical company, announced the completion of an angel round of financing of RMB 50 million .
